MaaT Pharma and Skyepharma Complete Construction of Europe's Largest Manufacturing Facility for Microbiome Ecosystem Therapies…
MaaT PharmaSeptember 12, 2023
MaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation Aiming to Improve Overall…
MaaT PharmaSeptember 7, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaAugust 2, 2023
July 27 2023: MaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results
MaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results Data presented at…
MaaT PharmaJuly 27, 2023
MaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in…
MaaT PharmaJuly 26, 2023
MaaT Pharma Joins Microbiome Therapeutics Innovation Group Lyon, France, July 20, 2023 6:00 pm CET…
MaaT PharmaJuly 20, 2023
MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux Lyon, France,…
MaaT PharmaJuly 13, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaJuly 6, 2023
MaaT Pharma Announces New Appointments to the Board and Executive Team Appointments to the Board…
MaaT PharmaJune 21, 2023
